9.1 Preeclampsia, Eclampsia & HELLP Syndrome in the Postpartum Period

9.1 Preeclampsia, Eclampsia & HELLP Syndrome in the Postpartum Period

Hypertensive emergencies in the puerperium represent one of the foremost causes of preventable maternal morbidity and mortality. While gestational hypertensive disorders commonly improve following the delivery of the placenta, the immediate and late postpartum periods present unique hemodynamic risks. Marked shifts in fluid compartmentalization, vascular tone, and delayed endothelial recovery can trigger sudden, life-threatening maternal cerebrovascular, hepatic, and cardiopulmonary complications.

---

Postpartum Preeclampsia: Onset, Pathophysiology & Clinical Criteria

Clinical Trajectory & Hemodynamic Shifting

Following delivery, the autotransfusion of approximately 500 mL of uteroplacental blood into the maternal central circulation—coupled with the mobilization of interstitial edema back into the intravascular compartment—peaks between postpartum days 3 and 6. This physiological volume expansion frequently unmasks or exacerbates underlying endothelial dysfunction.

• Timing of Onset: While preeclampsia most commonly develops antepartum, de novo postpartum preeclampsia can arise unexpectedly in patients without prior antepartum hypertensive history. Symptoms may manifest days after discharge and can occur up to 4 to 6 weeks postpartum.
• Pathophysiologic Mechanism: Systemic vascular endothelial injury leads to generalized arteriolar vasospasm, increased capillary permeability, microvascular thrombosis, and organ hypoperfusion.

Diagnostic Criteria for Postpartum Preeclampsia

Preeclampsia in the postpartum period is defined by new-onset blood pressure elevation occurring after birth accompanied by proteinuria or specific systemic end-organ dysfunction:

• Hypertension Threshold: Systolic blood pressure (SBP) >= 140 mmHg or diastolic blood pressure (DBP) >= 90 mmHg documented on two separate occasions at least 4 hours apart.
• Proteinuria: Urine protein excretion >= 300 mg per 24-hour collection, a urinary protein-to-creatinine ratio (UPCR) >= 0.3 mg/mg, or dipstick reading of 2+ (only if quantitative assays are unavailable).

Preeclampsia with Severe Features (Proteinuria NOT Required)

In accordance with American College of Obstetricians and Gynecologists (ACOG) guidelines, the presence of new-onset hypertension accompanied by ANY of the following severe features confirms the diagnosis of Preeclampsia with Severe Features, even in the complete absence of proteinuria:

1. Severe Hypertension: SBP >= 160 mmHg or DBP >= 110 mmHg confirmed on repeat measurement within 15 minutes.
2. Thrombocytopenia: Platelet count < 100,000/mcL.
3. Impaired Liver Function: Serum transaminases (AST and ALT) elevated to >= 2 times the upper limit of normal, or persistent, severe right upper quadrant (RUQ) or epigastric pain unresponsive to medication and not accounted for by alternative diagnoses.
4. Renal Insufficiency: Serum creatinine > 1.1 mg/dL or a doubling of the baseline serum creatinine in the absence of preexisting renal disease.
5. Pulmonary Edema: Acute respiratory compromise, tachypnea, basilar crackles, and SpO2 < 95% resulting from elevated pulmonary capillary hydrostatic pressure and decreased plasma oncotic pressure.
6. New-Onset Cerebral or Visual Disturbances: Persistent, severe frontal or occipital headache unresponsive to standard analgesics, photopsia, scotomata, diplopia, cortical blindness, or altered mental status.

---

The Emergency Antihypertensive Bundle for Severe Hypertension

Severe-Range Blood Pressure Threshold

CRITICAL EMERGENCY DEFINITION:
Systolic BP >= 160 mmHg OR Diastolic BP >= 110 mmHg.

Severe hypertension in the postpartum period requires verification on repeat measurement within 15 minutes to confirm persistence. Once confirmed, emergency antihypertensive pharmacotherapy must be initiated within 30 to 60 minutes (optimally within 30 minutes) to reduce the imminent risk of maternal hemorrhagic stroke, encephalopathy, and cardiopulmonary collapse.

First-Line Pharmacologic Protocols

Blood Pressure Target: The goal of acute emergency therapy is to lower blood pressure into a safe non-severe range (typically SBP 140–150 mmHg and DBP 90–100 mmHg), avoiding excessive hypotension that could impair vital organ and cerebral perfusion.

---

Seizure Prophylaxis: Magnesium Sulfate Protocols & Toxicity Monitoring

Mechanism of Action & Postpartum Dosing

Magnesium sulfate is the drug of choice for the prevention and treatment of eclamptic convulsions. It functions as a central nervous system depressant, inhibits acetylcholine release at the neuromuscular junction, reduces motor endplate sensitivity, and promotes cerebral arterial vasodilation through NMDA receptor blockade.

• IV Loading Dose: 4 to 6 grams in 100 mL of 5% Dextrose in Water (D5W) or 0.9% Normal Saline administered via an automated infusion pump over 20 to 30 minutes.
• IV Maintenance Infusion: 1 to 2 grams per hour continuous IV infusion.
• Duration of Therapy: Continued for at least 24 hours postpartum or for 24 hours following the last eclamptic seizure. If preeclampsia presents de novo postpartum, magnesium sulfate is maintained for 24 hours after the initiation of therapy and clinical stabilization.
• Therapeutic Serum Level: 4.8 to 8.4 mg/dL (equivalent to 4.0 to 7.0 mEq/L or 2.0 to 3.5 mmol/L).

Sequential Progression of Magnesium Sulfate Toxicity

Because magnesium sulfate is excreted 100% by the renal system, patients with renal compromise or oliguria are at extreme risk for rapid accumulation and life-threatening toxicity.

Standard Nursing Assessment Protocol for Patients on Magnesium Sulfate

1. Deep Tendon Reflexes (Patellar or Biceps): Evaluated hourly. Reflexes must be present (1+ to 2+). Absence (0) mandates immediate cessation of the infusion.
2. Respiratory Rate: Counted for a full 60 seconds every hour. A rate < 12 breaths/min requires immediate drug discontinuation and emergency intervention.
3. Continuous Pulse Oximetry: Hourly SpO2; target >= 95%.
4. Strict Hourly Urine Output: Measured via an indwelling Foley catheter with a urometer. Because magnesium is eliminated renally, oliguria (< 30 mL/hr or < 100 mL over 4 hours) results in toxic drug accumulation. A drop in urine output mandates an immediate provider notification and serum magnesium measurement.
5. Definitive Antidote Administration:

   MAGNESIUM TOXICITY ANTIDOTE:
   Calcium Gluconate 1 gram (10 mL of a 10% solution) administered intravenously slow push over 3 to 5 minutes. Have calcium gluconate readily available at the bedside of every patient receiving magnesium sulfate.

---

Eclampsia: Postpartum Presentation & Emergency Management

Clinical Presentation & Risk Windows

Eclampsia is the new onset of generalized tonic-clonic convulsions or coma in a patient with preeclampsia that cannot be attributed to other neurologic causes. Approximately 20% to 30% of eclamptic seizures occur in the postpartum period, with roughly one-third occurring after 48 hours post-delivery. Premonitory symptoms include severe persistent frontal headache, visual scotomata, photophobia, epigastric pain, and hyperreflexia with sustained clonus.

Step-by-Step Emergency Eclampsia Protocol

When a postpartum eclamptic seizure occurs, the maternal-newborn nurse must execute immediate emergency interventions focusing on maternal airway, safety, and pharmacologic seizure termination:

1. Call for Immediate Emergency Assistance: Activate the institutional Obstetric Emergency Response Code (Code OB / Rapid Response). Call the physician and team to the bedside.
2. Protect Maternal Airway and Positioning:
   • Turn the patient onto their left lateral decubitus position immediately to prevent aspiration of oral secretions and gastric contents.
   • Suction the oropharynx gently as needed once the clonic phase ceases.
   • NEVER attempt to force an oral airway, bite block, or tongue blade between clenched teeth during active convulsion; doing so causes dental avulsion, airway trauma, and laryngospasm.
3. Ensure Patient Safety:
   • Raise padded bed side rails to prevent falls.
   • Protect the patient's head from blunt trauma.
   • Do not physically restrain the patient's extremities.
4. Administer High-Flow Oxygen:
   • Apply oxygen at 10 L/min via a non-rebreather face mask following seizure cessation to reverse maternal hypoxia and metabolic acidosis.
5. Pharmacologic Seizure Arrest:
   • If the patient is NOT currently receiving magnesium sulfate, administer a 4 to 6 gram IV loading dose over 15 to 20 minutes, followed by a 2 g/hr continuous maintenance infusion.
   • If the patient is ALREADY receiving magnesium sulfate maintenance infusion, administer an additional 2 gram IV bolus over 3 to 5 minutes.
   • If seizures persist refractory to repeat magnesium doses, administer secondary anticonvulsants (e.g., IV lorazepam 2 to 4 mg over 2 minutes or IV diazepam 5 to 10 mg).
6. Post-Seizure Evaluation:
   • Assess maternal vital signs, oxygen saturation, and neurological status.
   • Insert an indwelling Foley catheter to monitor renal function.
   • Evaluate for complications: aspiration pneumonia, pulmonary edema, metabolic acidosis, and placental abruption (if unrecognized postpartum bleeding occurs).

---

HELLP Syndrome & Hepatic Rupture

Diagnostic Triad & Laboratory Criteria

HELLP syndrome represents a severe subtype of preeclampsia characterized by endothelial damage, microvascular thrombosis, and hepatic microcirculation compromise. Approximately 30% of HELLP cases develop de novo in the postpartum period, typically manifesting within the first 48 hours after delivery.

Clinical Manifestations & Hepatic Capsular Complications

• Presenting Symptoms: Patients with HELLP syndrome commonly present with severe epigastric or right upper quadrant (RUQ) pain (present in 85% to 90% of cases), nausea, vomiting, flu-like malaise, and headache. Jaundice may be present.
• Pathophysiology of Subcapsular Hematoma: Hepatic ischemia and intrahepatic hemorrhage can produce a collection of blood beneath Glisson's capsule (subcapsular liver hematoma). Increased intrahepatic pressure causes capsular stretching (manifesting as severe RUQ pain radiating to the back or right shoulder).
• Risk of Hepatic Rupture: Massive hemorrhage may cause the capsule to rupture, triggering acute hemoperitoneum, profound hypovolemic shock, and a maternal mortality rate exceeding 30%.
• Critical Nursing Precaution:

  CLINICAL WARNING: AVOID DEEP ABDOMINAL PALPATION
  In any postpartum patient presenting with preeclampsia or HELLP syndrome who complains of epigastric or right upper quadrant pain, do NOT perform deep abdominal or liver palpation. Palpation can induce rupture of a pre-existing subcapsular liver hematoma, resulting in catastrophic intra-abdominal exsanguination.

---

Clinical Pearls & Exam Alerts

EXAM ALERT: Postpartum Discharge Education on Late Preeclampsia
Over 50% of maternal deaths from preeclampsia occur postpartum, frequently after hospital discharge. Certification exams emphasize educating every postpartum patient on preeclampsia warning signs before discharge: severe headache unresponsive to acetaminophen, visual changes (flashes, spots, blurriness), epigastric or RUQ pain, sudden facial or hand swelling, and chest pain or shortness of breath. Symptoms can arise up to 6 weeks postpartum.

CLINICAL PEARL: NSAID Use in Postpartum Hypertensive Patients
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are standard first-line postpartum analgesics. However, in patients with preeclampsia featuring severe refractory hypertension or acute renal insufficiency (serum creatinine > 1.1 mg/dL), NSAIDs should be used with extreme caution or held, as they inhibit renal prostaglandins, exacerbate fluid retention, and further elevate blood pressure.

CLINICAL PEARL: Differentiating Eclampsia from Other Seizure Etiologies
While eclampsia is the most common cause of new-onset seizures in the puerperium, late-onset seizures occurring more than 48 to 72 hours postpartum or focal neurologic deficits warrant immediate brain neuroimaging (MRI/CT) to rule out cerebral venous sinus thrombosis (CVST), intracerebral hemorrhage, or posterior reversible encephalopathy syndrome (PRES).